The latest report from a group financed and backed by the pharmaceutical industry “continues to misrepresent” the 340B Drug Pricing Program and its “successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive health services,” AHA Executive Vice President Tom Nickels writes today in an AHA Stat blog post. Nickels says the report “attempts to mislead the debate by comparing changes in the ‘charity care’ provided by a small sample size of 160 disproportionate share hospitals (out of 2,448 hospitals) that participate in the 340B program,” and he highlights the many benefits 340B hospitals provide to the patients and communities they serve. "We hope policymakers won’t be diverted by this self-serving report from the important job of finding solutions to bring down the exorbitant cost of many prescription drugs that is threatening the availability of life-saving medications for millions of Americans,” Nickels writes.

Headline
The American Medical Association Nov. 17 released its latest annual report on health insurance competition, which found that 95% of commercial markets were…
Headline
The Medicare Part A deductible for inpatient hospital services will increase by $40 in calendar year 2026 to $1,776, the Centers for Medicare & Medicaid…
Headline
The Centers for Medicare & Medicaid Services Nov. 16 issued a proposed rule on program integrity oversight in Medicare, Medicaid, the Children’s Health…
Headline
The Department of Labor released an enforcement alert Nov. 13 to employers and health plan fiduciaries to ensure that plan participants and beneficiaries are…
Headline
The AHA and its co-plaintiffs Nov. 16 filed a reply brief urging a federal court to block implementation of the Health Resources and Services Administration’s…
Headline
The AHA Nov. 13 released “Interoperability and Prior Authorization: The American Hospital Association’s 2027 Guide to Electronic Prior Authorization Go-live…